Ginkgo Bioworks has acquired Patch Biosciences, with the intention to strengthen its gene therapy services, cell therapy services, and RNA therapeutics services. Ginkgo provides R&D services across industries, including in biopharma, and will incorporate Patch’s machine learning models and downstream assays into its existing platform, making new… Read More
Ginkgo Bioworks has announced a collaboration with Pfizer focused on the discovery of RNA-based drug candidates. In the collaboration, Pfizer will leverage Ginkgo's proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas. Ginkgo will receive an upfront payment and is eligible to… Read More
Ginkgo Bioworks and Merck have collaborated to improve the production of biologics. Ginkgo will apply its expertise and capabilities in cell engineering, ultra high-throughput multiplexed screening, protein characterisation and process optimisation to improve production efficiency and increase yields. “We’re thrilled to leverage our platform to… Read More
The Defense Advanced Research Projects Agency (DARPA) has announced that Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has been awarded a four-year contract worth up to $18 million to reimagine how to manufacture complex therapeutic proteins. As a performer on DARPA's Reimagining Protein Manufacturing… Read More
Ashwin Pillai is Test Engineer 3 in HTS & Assay Development at Ginkgo Bioworks, a company whose mission is to make biology easier to engineer. Ahead of his presentation in the Automation Technologies Track at SLAS2023, Pillai shares insight on data and how we can connect lab automation to decisions. Read More
Esperovax and Ginkgo Bioworks have agreed a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications. Initially, the companies will work to develop circRNAs harbouring payloads to specifically target colorectal cancer by inducing cell death only in cancerous cells. CircRNAs represent an… Read More
